Current situation and the latest progress in the treatment of pyoderma gangrenosum / 中华烧伤杂志
Chinese Journal of Burns
;
(6): 574-579, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-940963
ABSTRACT
Pyoderma gangrenosum (PG) is a rare chronic inflammatory non-infectious skin dermatosis, and there is no clear treatment guideline for this disease at home and abroad. There are a variety of clinical treatment methods for PG, including local therapy and systemic application of glucocorticoids, immunosuppressants, intravenous immuno- globulin, and biologics. Glucocorticoids are the first-line drugs commonly used in clinical practice, and immunosuppressants can be used alone or in combination with glucocorticoids. In recent years, more and more evidence has shown that biologics are a new trend in the treatment of PG, mainly including tumor necrosis factor α inhibitors, interleukin-1 (IL-1) inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, rituximab, and small molecular inhibitors. This article summarizes the current status and latest progress in the treatment of PG, hoping to provide clinicians with ideas for the treatment of PG.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Productos Biológicos
/
Piodermia Gangrenosa
/
Inhibidores de Interleucina
/
Glucocorticoides
/
Inmunosupresores
/
Inmunoterapia
Tipo de estudio:
Guía de Práctica Clínica
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Burns
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS